Note 2 - Liquidity	9 Months Ended
Sep. 30, 2017
Notes to Financial Statements
Liquidity and Going Concern [Text Block]	NOTE 2 - LIQUIDITY The Company continually projects anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations (CROs) and peptide synthesizer companies. They could also include business combinations, capital expenditures, and new drug development working capital requirements. As shown in the accompanying consolidated condensed financial statements, the Company incurred a net loss of $1,563,512 and $1,719,749 for the nine months ended September 30, 2017 and 2016, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $10,145,635 as of September 30, 2017. The Company anticipates further losses in the development of its business. The Company had a net working capital of $1,681,705 at September 30, 2017. Based on its current forecast and budget, Management believes that its cash resources will be sufficient to fund its operations at least until the fourth quarter of 2018. Absent generation of sufficient revenue from the execution of the Company’s business plan, it will need to obtain debt or equity financing by the fourth quarter of 2018.

NOTE

LIQUIDITY

The Company

continually projects anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations (CROs) and peptide synthesizer companies. They could also include business combinations, capital expenditures, and new drug development working capital requirements. As shown in the accompanying consolidated condensed financial statements, the Company incurred a net loss of

$1,563,512

and

$1,719,749

for the

nine

months ended

September 30, 2017

and

2016,

respectively. The Company has incurred losses since inception resulting in an accumulated deficit of

$10,145,635

as of

September 30, 2017.

The Company anticipates further losses in the development of its business. The Company had a net working capital of

$1,681,705

September 30, 2017.

Based on its current forecast and budget, Management believes that its cash resources will be sufficient to fund its operations at least until the

fourth

quarter of

2018.

Absent generation of sufficient revenue from the execution of the Company’s business plan, it will need to obtain debt or equity financing by the

fourth

quarter of

2018.